Shares of GeneDx Holdings (WGS) surged 5.11% in intraday trading on Wednesday, following a series of positive analyst actions. The genetic testing company saw its stock price climb as several prominent Wall Street firms raised their price targets, signaling increased confidence in the company's prospects.

Leading the bullish sentiment, BTIG reaffirmed its "Buy" rating on GeneDx Holdings while raising its price target to $165 from $140. This move was echoed by TD Cowen, which also increased its target to $165 from $140. Not to be left behind, Jefferies raised its price target to $150 from $120, further bolstering investor optimism.

The wave of analyst upgrades suggests growing confidence in GeneDx Holdings' business model and future growth potential. While specific reasons for the raised targets were not immediately available, such actions often reflect analysts' positive outlook on a company's financial performance, market position, or industry trends. Investors appear to be responding favorably to these endorsements, driving the stock's significant intraday gains.